Oncosyne

PreComb

This company develops a precision oncology platform using patient-derived microtumour models and automated analysis to predict drug responses for biopharmaceutical firms and clinical institutions.

Orakl Oncology

This company develops a predictive platform using patient tumor avatars and data to help pharmaceutical firms accelerate and de-risk cancer drug development.

Organo-ID

The company develops 3D organoid models and drug response tests for cancer patients and pharmaceutical researchers to improve personalised medicine and treatment efficacy.

Iscaff Pharma

This company develops patient-derived tumor scaffolds for pharmaceutical firms to improve the pre-clinical validation and development of aggressive cancer treatments.

Solid IO

This company develops organ-on-chip technology to provide patient-specific insights for pharmaceutical companies and oncologists to improve cancer treatment decisions and drug development.

D2G Oncology

This company develops genomic drug screening platforms and mouse models to identify genotype-specific cancer treatments for healthcare institutions and pharmaceutical researchers.

Known Medicine

This company develops a platform using 3D cell culture and artificial intelligence to predict drug responses for oncologists and biopharmaceutical developers.

Kiyatec

This company develops 3D cell culture platforms to predict patient-specific responses to cancer therapies for oncologists and biopharmaceutical companies.